When alpha- or auger-emitting PSMA-based radioligands are used, which benefit from a higher linear energy transfer, the radioligand-complex will need to be transported from the endothelial cells into the tumour microenvironment to reach the tumour DNA, such as occurs in prostate cancer.45 This evidence concerns the gene FOLH1 and prostate carcinoma.